Navigation Links
CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine
Date:1/7/2009

Results expected to Support Licensing Activities

VIENNA, Va., Jan. 7 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Alternext US: CVM) announced today the initiation of a definitive study of its new rheumatoid arthritis treatment vaccine (CEL-2000) to determine the long-lasting beneficial effects on animals with the disease. The study is being conducted at the request of a large pharmaceutical company which is evaluating the possibility of acquiring a global license for the vaccine from CEL-SCI. The long-term results, previously presented at the 6th annual GTCbio Vaccine conference, for the CEL-2000 vaccine were better than or comparable to those for Enbrel(R), a leading treatment for people with rheumatoid arthritis.

"We are very excited to see a prominent pharmaceutical company express interest in licensing the vaccine," said Geert Kersten, CEL-SCI's Chief Executive Officer. "As a result of the very good data with this novel approach, we believe that the prospects for licensing the vaccine are promising."

The definitive experiment will confirm the efficacy and durability of the response to the vaccine and will further assess the safety of the CEL-2000 vaccine, in preparation for possible human trials. CEL-2000 may also offer a number of other potential advantages over existing rheumatoid arthritis treatments, such as Enbrel. The data from animal studies of rheumatoid arthritis using CEL-2000 treatment vaccine demonstrated that CEL-2000 is an effective treatment against arthritis with fewer administrations than those required by other anti-rheumatoid arthritis treatments, including Enbrel(R). CEL-2000 is also potentially a more disease type specific therapy is calculated to be significantly less expensive and may be useful in patients unable to tolerate or who may not be responsive to existing anti-arthritis therapies.

Rheumatoid arthritis treatments comp
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

5

GOOD

Page: 1 2 3

Related medicine news :

1. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
2. CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
3. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
4. CEL-SCI Corporation Releases Letter to Shareholders
5. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
6. Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
7. Surf Sweets Launches Natural, Organic Candy Line at More Than 250 Toys"R"Us Stores Across the Country
8. ChildRC.com Launches The Child Resource Center
9. First Service Design Firm Launches in United States
10. The Doctors Company Launches Southeast Legal Summit to Provide Industry's Best Claims Defense for Physicians
11. Florida Breast Augmentation Surgeon Launches State-of-the-Art Website Reflecting his Unique Approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Pasierb, President ,, NEW YORK, Dec. 14 ... the Future study (MTF) -- the largest survey on ... 12th graders -- underscores that teens, intentional abuse of ... a cause for concern, with an alarming number of ... relatives. ,, Teen Abuse of Medication ...
(Date:12/14/2009)... 2009, the United States Court of Appeals, Tenth Circuit, ... are "plans" and therefore subject to federal jurisdiction. (US ... that contracts issued by insurance companies may be subject ... US vs. Frost is the first case an ... "plan," because, as the government claimed in this case, ...
(Date:12/14/2009)... bump in odds is small and shouldn,t worry most ... -- Older women who take antidepressants may have a ... death compared to women not on the medications, a ... different from clinical significance," stressed Dr. Jordan W. Smoller, ... and lead author of a report in the Dec. ...
(Date:12/14/2009)... treated and highly stigmatized, according to psychiatrists Charles ... Ph.D. So these Washington University physicians have written ... "Demystifying Psychiatry," Zorumski and Rubin, who have more ... and helping patient families, say some of the ... from a lack of understanding psychiatry and what ...
(Date:12/14/2009)... Quickly and Accurately for Biopsy , ... ... Dilon Diagnostics announced today that the U.S. Food and Drug ... for molecular imaging biopsy guidance. , , ,GammaLMc® is ... Gamma Camera. The GammaLMc® (GL) system will help doctors accurately ...
Breaking Medicine News(10 mins):Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3Health News:Insurance Now Subject to Federal Jurisdiction 2Health News:Antidepressants May Raise Women's Stroke Risk 2Health News:Antidepressants May Raise Women's Stroke Risk 3Health News:Book demystifies psychiatry for the general public 2Health News:Book demystifies psychiatry for the general public 3Health News:Dilon Diagnostics Gamma-Guided Localization System Cleared by FDA 2
... the President,s Cancer Panel, investigators at the U.S. EPA,s Office of ... EPA Administrator to use regulatory authorities authorized by Congress to protect ... ... Atlanta, GA (PRWEB) January 22, 2009 -- A growing ...
... Although primary prostate surgery or radiotherapy is successful in many ... of the disease, which is most often first detected by ... affects 30% to 40% of patients after surgery. One risk ... prostate after surgery, will affect about a third of men. ...
... BROOK, Ill., Jan. 22 University HealthSystem,Consortium (UHC) ... it has,awarded agreements for patient satisfaction measurement services ... supplier has been awarded,a 3-year agreement with options ... 1, 2009. , Under ...
... International Retail Expansion, With Near Term Focus on Top ... ExtensionIRVINE, Calif., Jan. 21 University Medical ... and efficacy-based skin and beauty care products sold at ... U.S., announced today that it has appointed Tom Roche ...
... 21 The following statement can be attributed ... BlueCross:"Capital BlueCross has consistently said two things: We ... other merger. But we have urged public policy ... this proposed merger without conditions, because without conditions ...
... Omnicell, Inc. (Nasdaq: OMCL ), a leading provider of ... to discuss the Company,s fourth quarter 2008 financial results. , ... webcast, ... Randall Lipps, chairman, president and chief executive officer, ...
Other Medicine News:Health News:Scientists and Investigators Cite Need for Radon Regulation to Prevent Lung Cancer- Call Current EPA Efforts Ineffective 2Health News:Scientists and Investigators Cite Need for Radon Regulation to Prevent Lung Cancer- Call Current EPA Efforts Ineffective 3Health News:Scientists and Investigators Cite Need for Radon Regulation to Prevent Lung Cancer- Call Current EPA Efforts Ineffective 4Health News:Treatments after prostate surgery reported in the Journal of Urology 2Health News:Treatments after prostate surgery reported in the Journal of Urology 3Health News:University HealthSystem Consortium Announces Dual Award for Patient Satisfaction Measurement Services 2Health News:University Medical Pharmaceuticals Appoints Tom Roche as Senior Vice President, Global Sales and Marketing 2Health News:University Medical Pharmaceuticals Appoints Tom Roche as Senior Vice President, Global Sales and Marketing 3Health News:Capital Blue Cross Issues Statement on Withdrawal of Merger 2Health News:Omnicell to Release Fourth Quarter 2008 Earnings Results on January 29 2
(Date:12/14/2009)... 14 Embarrassing and sometimes uncomfortable colonoscopies may ... researchers are taking note of a new screening test ... The Knoxville-based company, EDP Biotech Corporation ... an affordable medical device doctors can use to screen ... "When you consider that 30% of colon cancer deaths ...
(Date:12/14/2009)... Seven leading cancer physicians ... Oncology Research participated in studies ... 2009 San Antonio Breast Cancer ... the Henry B. Gonzalez Convention ... . Fifteen others presented their ...
(Date:12/14/2009)... Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... Application (NDA) for Staccato® loxapine (AZ-004) to the US ... inhalation product candidate being developed for the rapid treatment ... The IND for Staccato loxapine was ... has delivered a predictable and consistent safety and efficacy ...
Breaking Medicine Technology:EDP Biotech Takes Next Step in the Development of ColoMarker 2EDP Biotech Takes Next Step in the Development of ColoMarker 3US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 2US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 3US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 4US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 5US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 6US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 7US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 8US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 9Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 2Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 3Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 4Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 5Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 6Amilpar Operating Revenues Grew 9 25 in the Second Quarter and 11 25 in the First Half of 2009 54276 1Amilpar Operating Revenues Grew 9 25 in the Second Quarter and 11 25 in the First Half of 2009 54276 2Finding may explain anti cancer activity of thiazole antibiotics 54273 1Finding may explain anti cancer activity of thiazole antibiotics 54273 2HearUSA Makes Hearing Aids and Care Available to AARP Members 54269 1HearUSA Makes Hearing Aids and Care Available to AARP Members 54269 2HearUSA Makes Hearing Aids and Care Available to AARP Members 54269 3HearUSA Makes Hearing Aids and Care Available to AARP Members 54269 4
... to anti-clotting drug, CHICAGO, March 29 ... dose of a medication that prevents blood clotting,significantly ... coronary interventions (PCI), according to a multicenter study,reported ... the SCAI,Annual Scientific Sessions in Partnership with ACC ...
... With drug-eluting stents, is the ,crush, or ,culotte, technique ... performed for an,arterial narrowing at the branchpoint of two ... be challenging to achieve full coverage of,both vessels without ... study,will provide interventional cardiologists with new information on which ...
Other Medicine Technology:Tailored Clopidogrel Dosing Improves PCI Outcomes 2Tailored Clopidogrel Dosing Improves PCI Outcomes 3Stenting Techniques Vie in Branchpoint Lesions 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: